Pancreatic Cancer Research

Clinical trialPhase 2Completed

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Outcome
Results posted; single-arm, no comparison
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
20 October 2023
Ended
3 October 2025
Enrollment
12 participants
Sites
4
Primary outcomes
Percentage of Participants With Objective Response Rate
Sponsor type
Industry
Results posted
25 August 2026
Last update
25 August 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 25 August 2026
ORR
Percentage of Participants With Objective Response RateNeuroendocrine Tumors: 8.3 (0.2 to 38.5), n = 12Values: Percent of participants, 95% Confidence IntervalTime frame: From the start of study treatment to radiographically confirmed disease progression (PD) per RECIST v1.1, assessed at screening, every 6 weeks (±7 days) for the first 12 weeks, and every 12 weeks (±7 days) thereafter, up to 22 months.No analysis posted for this outcome (outcome 1)
Participants
Neuroendocrine Tumors: 12 started, 1 completed
Serious adverse events
Neuroendocrine Tumors: 4 of 12Participants with at least one serious adverse event, of those at risk, as posted
6 secondary outcomes
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-R…
Neuroendocrine Tumors 100, n=12 [Percent of participants]
Duration of Response (DOR)
Neuroendocrine Tumors NA (NA to NA), n=1 [median Months, 95% Confidence Interval]
DCR · Disease Control Rate (DCR)
Neuroendocrine Tumors 50.0 (21.1 to 78.9), n=12 [Percent of participants, 95% Confidence Interval]
Time to Response (TTR)
Neuroendocrine Tumors 1.51 (NA to NA), n=12 [median Months, 95% Confidence Interval]
PFS · Progression-free Survival(PFS)
Neuroendocrine Tumors 10.0 (5.4 to NA), n=12 [median Months, 95% Confidence Interval]
OS · Overall Survival(OS)
Neuroendocrine Tumors NA (9.7 to NA), n=12 [median Months, 95% Confidence Interval]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors

Detailed description public domain (ClinicalTrials.gov)

This is a prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus and patients with functional or non-functional, well-differentiated, locally advanced unresectable in metastatic NETs of the GI tract, lung, or pancreas.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Percentage of Participants With Objective Response Rate [From the start of study treatment to radiographically confirmed disease progression (PD) per RECIST v1.1, assessed at screening, every 6 weeks (±7 days) for the first 12 weeks, and every 12 weeks (±7 days) thereafter, up to 22 months.]. Number, Percent of participants (95% Confidence Interval). Neuroendocrine Tumors (n=12): 8.3 (0.2 to 38.5).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events. [From first dose of study treatment through end of treatment (estimated up to 18 months) plus safety follow-up of 30 days after the last dose.]. Number, Percent of participants. Neuroendocrine Tumors (n=12): 100.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Duration of Response (DOR) [From first documented response (CR or PR) to radiographically confirmed disease progression (PD) per RECIST v1.1 or death from any cause, assessed at screening, every 6 weeks for the first 12 weeks, and every 12 weeks thereafter, up to 22 months]. Median, Months (95% Confidence Interval). Neuroendocrine Tumors (n=1): NA (NA to NA) [The Duration of Response (DOR) was evaluable in only one subject, and the median could not be estimated due to the absence of events.].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Disease Control Rate (DCR) [From the start of study treatment to radiographically confirmed disease progression (PD) per RECIST v1.1, assessed at screening, every 6 weeks for the first 12 weeks, and every 12 weeks thereafter, up to 22 months]. Number, Percent of participants (95% Confidence Interval). Neuroendocrine Tumors (n=12): 50.0 (21.1 to 78.9).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Time to Response (TTR) [From the first dose of study treatment to the initial documentation of complete response (CR) or partial response (PR) per RECIST v1.1 , assessed at screening, every 6 weeks for the first 12 weeks, and every 12 weeks thereafter, up to 22 months]. Median, Months (95% Confidence Interval). Neuroendocrine Tumors (n=12): 1.51 (NA to NA) [The 95% confidence interval was not estimable due to the limited number of responders (N=1).].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression-free Survival(PFS) [From first dose of study treatment until the date of first documented disease progression or death from any cause, whichever occurs first, assessed every 6 weeks for the first 12 weeks and every 12 weeks thereafter, up to approximately 21 months]. Median, Months (95% Confidence Interval). Neuroendocrine Tumors (n=12): 10.0 (5.4 to NA) [The upper bound of the confidence interval could not be estimated because the survival curve did not reach the upper threshold due to a limited number of events.].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival(OS) [From first dose of study treatment until the date of death from any cause, assessed approximately every 12 weeks following the end-of-treatment visit, up to approximately 24 months.]. Median, Months (95% Confidence Interval). Neuroendocrine Tumors (n=12): NA (9.7 to NA) [The median and the upper limit of the 95% confidence interval were not estimable due to a limited number of events and a high proportion of censored patients.].